- Home
- STG vs AVTX Comparison
STG vs AVTX Comparison
Compare STG & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- AVTX
- Stock Information
- Founded
- STG 2003
- AVTX 2011
- Country
- STG China
- AVTX United States
- Employees
- STG N/A
- AVTX N/A
- Industry
- STG Other Consumer Services
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- STG Real Estate
- AVTX Health Care
- Exchange
- STG Nasdaq
- AVTX Nasdaq
- Market Cap
- STG 91.6M
- AVTX 77.7M
- IPO Year
- STG 2018
- AVTX 2015
- Fundamental
- Price
- STG $5.89
- AVTX $6.75
- Analyst Decision
- STG
- AVTX Strong Buy
- Analyst Count
- STG 0
- AVTX 4
- Target Price
- STG N/A
- AVTX $33.00
- AVG Volume (30 Days)
- STG 9.4K
- AVTX 137.5K
- Earning Date
- STG 11-22-2024
- AVTX 11-07-2024
- Dividend Yield
- STG N/A
- AVTX N/A
- EPS Growth
- STG N/A
- AVTX N/A
- EPS
- STG 4.57
- AVTX N/A
- Revenue
- STG $292,030,936.00
- AVTX $820,000.00
- Revenue This Year
- STG N/A
- AVTX N/A
- Revenue Next Year
- STG N/A
- AVTX N/A
- P/E Ratio
- STG $1.29
- AVTX N/A
- Revenue Growth
- STG N/A
- AVTX N/A
- 52 Week Low
- STG $4.25
- AVTX $4.01
- 52 Week High
- STG $12.55
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- STG 49.83
- AVTX 32.78
- Support Level
- STG $5.50
- AVTX $5.99
- Resistance Level
- STG $5.79
- AVTX $7.17
- Average True Range (ATR)
- STG 0.30
- AVTX 0.91
- MACD
- STG 0.03
- AVTX -0.05
- Stochastic Oscillator
- STG 65.83
- AVTX 23.17
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).